Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and CE information More Information
Learn about treatment options, treatment failure, associated adverse effects and more.
Choose from the criteria below to find an activity that fits you best.
Three dates available!
Thursday, April 22, 2021, 11:00 AM - 12:00 PM CT
Tuesday, April 27, 2021, 2:00 PM - 3:00 PM CT
Thursday, April 29, 2021, 12:00 PM - 1:00 PM CT
Melanoma is the fifth most common cancer in the United States and the incidence
is increasing. Management strategies depend on the staging at diagnosis, and although
most cases are diagnosed at an earlier stage, advanced cutaneous melanoma is far more
aggressive and requires quick intervention. Since 2010, nearly a dozen new treatments/treatment
regimens for melanoma have been approved by the FDA, including 4 systemic immunotherapy
treatments/combinations, single-agent BRAF inhibitors, combination BRAF/MEK inhibitor
regimens, and 1 intralesional immunotherapy involving a modified oncolytic herpes
Pharmacists, including clinical, oncology, and specialty pharmacists, play an expanded role in the treatment and management of patients with melanoma. This activity will focus on individualized treatment selection, mechanisms of action and drug targets, adverse effect profiles, management, and access will help ameliorate gaps in clinical knowledge for pharmacists who find it challenging to stay up to date on the latest data.
The target audience for this activity includes pharmacists, including clinical and health-system pharmacists, board-certified oncology pharmacists, specialty pharmacy and managed care professionals, and other pharmacists responsible for the care and management of patients with advanced melanoma. At the completion of this activity, the participant will be able to:
Heather Armbruster, PharmD, BCOP
Specialty Practice Pharmacist, Melanoma and Neuroendocrine Tumors
The James Cancer Hospital at The Ohio State University
Jessica Davis, PharmD, BCOP, CPP
Clinical Pharmacist Coordinator, Adult Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-21-103-L01-P
has been assigned to this live knowledge-based activity (initial release date 4-22-21).
This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize
ACPE providers. The activity is provided at no cost to participants. Participants
must complete the online post-test and activity evaluation within 30 days of the activity
to receive pharmacy CE credit. No partial credit will be given. Statements of completion
will be issued online at www.ProCE.com, and proof of completion will be posted in
NABP CPE Monitor profiles.
It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Faculty disclosures will be announced prior to the start of the CE activity.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Webinar Equipment Requirements
-Computer with broadband Internet access
-Soundcard and speakers or headphones for your computer (or dial-in via telephone for audio)
Click here for detailed software requirements.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.